Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | NPFFR2 | Q9Y5X5 | 3/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.33 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30296285 | 1.00 | GAA (0.40) | GAAIDO1HTR3EHTR3BHTR3A | |
| SCHEMBL28970675 | 0.91 | HTR3E (0.42) | GAAIDO1HTR3EHTR3BHTR3A | |
| SCHEMBL29770447 | 0.84 | GAA (0.46) | GAAIDO1HTR3EHTR3BHTR3A | |
| SCHEMBL440693 | 0.84 | GAA (0.46) | GAAIDO1HTR3EHTR3BHTR3A | |
| SCHEMBL24557866 | 0.83 | GAA (0.40) | GAAIDO1HTR3EHTR3BHTR3A | |
| SCHEMBL21728912 | 0.82 | GAA (0.57) | GAAIDO1HTR3EHTR3BHTR3A | |
| SCHEMBL29398605 | 0.82 | GAA (0.57) | GAAIDO1HTR3EHTR3BHTR3A | |
| SCHEMBL8975023 | 0.81 | HTR3E (0.42) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7272204 | 0.79 | NOTUM (0.42) | IDO1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL31069948 | 0.79 | KIF11 (0.45) | GAAKIF11GLAPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070909-A1 | GPR65 MODULATORS | PATHIOS THERAPEUTICS LTD (GB) | 2026-03-12 | — | — | US | disclosed |
| US-20250304574-A1 | 3,4,6,7-TETRAHYDRO-2,7-NAPHTHYRIDINE-2(1H)-CARBOXAMIDE DERIVATIVES AS GPR65 INHIBITORS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | Pathios Therapeutics Limited (GB) | 2025-10-02 | — | — | US | disclosed |
| EP-4596551-A1 | COMPOUNDS WITH ANTI-KRAS MUTANT TUMOR ACTIVITY | Trasveda Ltd. (KY) | 2025-08-06 | — | — | EP | disclosed |
| EP-4536661-A1 | GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2025-04-16 | — | — | EP | disclosed |
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| WO-2024199109-A1 | HETEROCYCLIC COMPOUND SERVING AS WRN HELICASE INHIBITOR, AND PREPARATION METHOD FOR AND USE OF HETEROCYCLIC COMPOUND | 上海济煜医药科技有限公司 | 2024-10-03 | — | — | WO | disclosed |
| CN-118684688-A | Heterocyclic compounds serving as WRN helicase inhibitors, and preparation method and application thereof | 上海济煜医药科技有限公司 | 2024-09-24 | — | — | CN | disclosed |
| EP-4419203-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| WO-2024149389-A1 | SUBSTITUTED BRIDGE RING INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 苏州泽璟生物制药股份有限公司 | 2024-07-18 | — | — | WO | disclosed |
| WO-2023242537-A1 | GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023187391-A1 | 3,4,6,7-TETRAHYDRO-2,7-NAPHTHYRIDINE-2(1H)-CARBOXAMIDE DERIVATIVES AS GPR65 INHIBITORS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | Pathios Therapeutics Limited (GB) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023187391-A1 | 3,4,6,7-TETRAHYDRO-2,7-NAPHTHYRIDINE-2(1H)-CARBOXAMIDE DERIVATIVES AS GPR65 INHIBITORS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | Pathios Therapeutics Limited (GB) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023179629-A1 | SUBSTITUTED BRIDGED RING INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 苏州泽璟生物制药股份有限公司 | 2023-09-28 | — | — | WO | disclosed |
| WO-2023067322-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023067322-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-04-27 | — | — | WO | disclosed |
| EP-0246061-B1 | A BENZOYLUREA DERIVATIVE AND ITS PRODUCTION AND USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-03-18 | — | — | EP | disclosed |
| EP-0246061-A2 | A benzoylurea derivative and its production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | GPR65, GPR3, NR1H2 | GAA 4385/4885IDO1 2919/4885HTR3E 196/4885 |
| US-20260070909-A1 | GPR65 MODULATORS | GPR65, GPR68, GPR84 | GAA 4412/4885IDO1 770/4885HTR3E 559/4885 |
| US-20250304574-A1 | 3,4,6,7-TETRAHYDRO-2,7-NAPHTHYRIDINE-2(1H)-CARBOXAMIDE DERIVATIVES AS GPR65 INHIBITORS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | GPR65, GPR52, GPR68 | GAA 4241/4885IDO1 755/4885HTR3E 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.